Search 

Clinical Accelerator conducts all phases of clinical trials for pharma, biotech and medtech companies. We have a very simple mission: to accelerate clinical development projects and to reduce their cost appreciably for our clients. We use several strategies to achieve very compact timelines in our clinical studies: - optimization of study design (only necessary outcome measures and end-points, right number of patients, optimal follow-up duration) - selection of effective investigative sites located in our region of operation. All our sites, conducting trials to the highest standards of GCP, have a large patient recruiting capacity and a proven track record of efficient timely recruitment of qualified patients. - accelerated start up (fast regulatory and IRB/EC approval times, streamlined logistics, expedited contracting, fast site activation, USA IND or EU CTA are optional in our region of operation) - effective patient enrolment and retention (dedicated department, proven region-specific patient recruitment strategies) We are specialists in effective and timely patient recruitment, and commit to achieving patient enrolment targets within fixed timelines. We routinely rescue stalled clinical trials. We are able to reduce the cost of our clinical projects significantly due to our: - flat organizational hierarchy, reasonable service rates and very modest internal overhead costs - commitment to agreed fixed budgets (rare need for change orders) - modest investigator grants and low hospital overheads in our region of operation (very large savings can be achieved in many therapeutic areas) - use of as few locations and as few investigative sites as possible without compromising patient recruitment rates (this limits set-up costs and lowers per patient cost) - short study timelines, which lead to reduced management costs - potential risk sharing (optional strategy) The cost of our studies is among the most attractive globally. We commit to our budgets and fix them for our clients.

Invicro was founded with a mission of improving the role and function of imaging in translational drug discovery and development.  To this effort we offer a suite of services and software with applications ranging from tissue to human, from target identification to Phase IV trials across the entire electromagnetic spectrum of imaging techniques.

Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise.  Founded in 2004, Sygnature undertakes complete drug discovery programmes and target validation, hit identification, hit-to-lead and lead optimisation projects for pharmaceutical and biotech companies.  Core capabilities include medicinal and synthetic chemistry, in vitro biology/screening, computational chemistry, DMPK and protein crystallography.  Sygnature has an enviable track record of success in delivering multiple clinical candidates.

Winner of OBN Best Synthetic Biology Company Award.